South Africa has emerged as a crucial country for clinical trials in AstraZeneca’s global operations, playing a pivotal role in advancing medical research and delivering innovative treatments. Through groundbreaking efforts in respiratory, cardiovascular, and oncology research, AstraZeneca’s clinical trials in South Africa are revolutionising patient care locally while making a meaningful contribution to the global health landscape.
Over recent years, South Africa has seen a remarkable increase in the number of clinical trials conducted by AstraZeneca. This growth has been a direct result of the country’s established healthcare infrastructure, a diverse patient population, and the presence of highly skilled investigators. AstraZeneca’s investment in South African trials has more than doubled since 2021, underscoring South Africa’s increasing importance in the company’s global research strategy.
AstraZeneca has 31 ongoing clinical trials across different therapeutic areas in South Africa. This represents a 94% growth since 2021, with research spanning critical areas such as cardiovascular, respiratory, and oncology diseases. This substantial activity ranks AstraZeneca in the Top 2 in the pharmaceutical sector regarding the number of active clinical trials, highlighting its leadership in advancing critical research across these areas.
World Lung Cancer Day: AstraZeneca on improving outcomes in Africa, early detection
The company’s focus on addressing major global health concerns such as resistant hypertension, heart failure, chronic kidney disease, and various cancers has cemented South Africa as a leader in medical research innovation.
Deepak Arora, African Cluster Country President at AstraZeneca, said, “South Africa has emerged as a vital contributor to AstraZeneca’s global clinical research initiatives. Our focus on diverse, high-impact trials in respiratory, cardiovascular, and oncology therapies not only advances global medical knowledge but also brings novel treatments to local patients. We are committed to continuing our investment in South Africa’s healthcare ecosystem, driving scientific innovation while improving access to life-saving therapies.”
AstraZeneca’s commitment to South Africa goes beyond conducting trials. The company is leveraging its local expertise to advance treatments that benefit both the local population and the global market. One of the major successes has been in respiratory research, where South Africa has become a key contributor. For example, AstraZeneca’s clinical trials for conditions such as asthma and chronic obstructive pulmonary disease (COPD) have seen South African teams leading the charge. The country has also played a pivotal role in cardiovascular trials, with thousands of patients contributing to research that has informed global treatment protocols.
In oncology, while the number of clinical trials has been lower compared to other areas, the impact is still significant. South Africa has contributed to several major studies, particularly in lung, breast, and prostate cancer research. One of the highlights is the LOGOS study where South Africa is a global top recruiter (ex-China) contributing 296 patients (13.5% of the global cohort) a major achievement that showcases the country’s expertise in managing complex trials.
Fatima Cassim, Head of Clinical Operations at AstraZeneca South Africa, said, “Clinical trials are a cornerstone of AstraZeneca’s mission to deliver innovative healthcare solutions. We have successfully transformed our operation in South Africa, expanding from just a handful of studies to over 30 ongoing trials today. This remarkable growth underscores the increasing importance of South Africa in our global research efforts and highlights the dedication of our teams in driving this progress.”
Beyond its contributions to global research, AstraZeneca’s clinical trials in South Africa have had a profound impact on the local healthcare system. One of the most significant benefits is the provision of novel treatments to patients who might not otherwise have access to cutting-edge therapies. In many cases, patients involved in these trials receive continued access to innovative treatments even after the trial concludes, ensuring long-term health benefits.
Clinical trials have also helped alleviate the burden on the public healthcare system by offering high-quality, regulated care to patients with severe outcomes. Moreover, the trials are creating a more skilled and experienced medical workforce. Through exposing local healthcare professionals to global research standards and practices, AstraZeneca is helping build capacity in South Africa’s medical community.
AstraZeneca’s dedication to research and development, combined with South Africa’s growing expertise, positions the country as a key player in AstraZeneca’s global strategy. As the company deepens its investment in South African clinical trials, the future looks promising for both the local healthcare system and the global medical research community.
